Treatment modality and outcomes
| Variables | Total (n=25) | Group A (n=10) | Group B (n=15) | p-value |
|---|---|---|---|---|
| Empirical antibiotics | 0.512a) | |||
| 3rd cephalosporins | 14 (56.0) | 5 (50.0) | 9 (60.0) | |
| Fluoroquinolones | 4 (16.0) | 1 (10.0) | 3 (20.0) | |
| Carbapenems | 7 (28.0) | 4 (40.0) | 3 (20.0) | |
| Broad-spectrum antibiotics | 10 (40.0) | 4 (40.0) | 6 (40.0) | |
| Treatment | ||||
| TUD | 14 (56.0) | 2 (20.0) | 12 (80.0) | 0.040a) |
| PCD | 1 (4.0) | 1 (10.0) | 0 (0) | |
| Hospital day (d) | 20.96±15.30 | 13.80±9.95 | 25.73±16.63 | 0.024b) |
| Septic shock | 11 (44.0) | 0 (0) | 11 (73.3) | 0.001c) |
| ICU admission | 5 (20.0) | 0 (0) | 5 (33.3) | 0.061c) |
| Mortality | 1 (4.0) | 0 (0) | 1 (6.7) | 1.000c) |
| IV antibiotics duration (d) | 19.32±14.01 | 12.50±7.95 | 23.87±15.51 | 0.013d) |
| PO antibiotics duration (d) | 8.88±5.08 | 10.90±4.84 | 7.53±4.93 | 0.116d) |
| Prostatic abscess recurrence | 0 (0) | 0 (0) | 0 (0) | 1.000d) |
| Urological chronic complication | 0 (0) | 0 (0) | 0 (0) | 1.000d) |
Values are presented as number (%) or mean±standard deviation.
Group A: patients with prostate abscess size ≤2 cm, Group B: patients with prostate abscess size >2 cm, TUD: trans urethral deroofing, PCD: percutaneous drainage, ICU: intensive care unit, IV: intravenous, PO: oral.
a)Chi-square test. b)Studentʼs t-test. c)Fisherʼs exact test. d)Mann–Whitney U-test.